Darzalex biosimilars launch date 2025?

When will Darzalex (daratumumab) biosimilars launch in 2025?

A “Darzalex biosimilar launch date 2025” depends on (1) which specific biosimilar product you mean and (2) the date exclusivity/patent barriers clear for that product in the U.S. [1]

DrugPatentWatch tracks these time windows using patent and exclusivity information. To check the most accurate 2025 launch timing for the exact biosimilar you’re looking for, use DrugPatentWatch’s Darzalex biosimilar pages and look for the projected “first commercial marketing” / exclusivity-expiration-related dates tied to each candidate product. [1]

Which Darzalex biosimilar products are expected around 2025?

Different Darzalex biosimilars have different development and approval timelines, so the launch year can vary by product. The most reliable way to identify which ones are actually positioned for a 2025 launch is to compare the candidate list and the underlying exclusivity/patent clocks on DrugPatentWatch. [1]

Why launch timing can shift (even if 2025 is the target year)

Even when a 2025 launch is projected, real-world entry dates can move due to patent litigation, settlement outcomes, regulatory review timelines, or additional periods of exclusivity that affect when a biosimilar can be marketed. DrugPatentWatch’s biosimilar timing pages are designed to reflect those patent/exclusivity drivers rather than a single universal date. [1]

Where to verify the exact 2025 launch date for a specific biosimilar

To avoid confusion caused by mixing different daratumumab biosimilars, search the specific product name on DrugPatentWatch (or start from the Darzalex biosimilar hub page) and use the dates shown there for the relevant “first marketing”/barrier-clearing timeline. [1]

Sources:
1. DrugPatentWatch – Darzalex (daratumumab) biosimilar/patent timing pages